May 1st 2025
Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
New rule on importing Active Pharmaceutical Ingredients (API) to the EU countries.
October 10th 2013With the enforcement of the European Directive 2011/62/EU relating to medicinal products for human use regarding falsified medicinal products, new requirements are introduced for active substances. The new regulation requires among other things, documentation of the supply chain traceability.
Novel Solvent-Free Method to Manufacture Metastable Drug Forms
September 30th 2013Researchers from the University of Bradford, UK, have developed a solvent-free, continuous method to manufacture the more soluble and bioavailable form of artemisinin. The metastable form produced using high-temperature extrusion has been shown to have greater stability and longer shelf-life.
Molecular Profiles Chosen to Develop Topical and Oral Formulations of Telormedix's Psoriasis Product
September 25th 2013Molecular Profiles has secured a major pan-European formulation project, in which the company will be responsible for developing a topical and an oral formulation for Telormedix's psoriasis products, TMX-302.